Congressional ethics investigators have concluded there is “substantial reason to believe” Rep. Chris Collins (R-NY) “engaged in insider trading and either took or requested official actions” to benefit a company in which he’s the largest shareholder, USA Today reports.
“Those may violations of House rules, standards of conduct and federal law.”
“Collins — who was the first member of Congress to endorse Donald Trump’s presidential campaign — is a board member of an Australian biotechnology company called Innate Immunotherapeutics.”
Save to Favorites